Nirsevimab Effectiveness Against Medically Attended Respiratory Syncytial Virus Illness and Hospitalization Among Alaska Native Children — Yukon-Kuskokwim Delta Region, Alaska, October 2023–June 2024
Link
Description
Reports on effectiveness of nirsevimab in preventing respiratory syncytial virus (RSV) associated hospitalization for Alaska Native infants in their first RSV season and against medically attended illness for children in their first and second seasons in Alaska's Yukon-Kuskokwim Delta. Includes data by community type for the hub town with regional hospital and outlying villages.
Author(s)
Brian Lefferts, Sara Bressler, James W. Keck, et al.
Citation
MMWR (Morbidity and Mortality Weekly Report), 73(45), 1015-1021
Date
11/2024
Type
Document
Organization
Centers for Disease Control and Prevention
Tagged as
American Indian or Alaska Native · Children and youth · Infectious diseases · Rural-urban differences · Statistics and data · Wellness, health promotion, and disease prevention · Alaska